Followers | 160 |
Posts | 3933 |
Boards Moderated | 2 |
Alias Born | 07/08/2017 |
Thursday, November 11, 2021 1:58:31 PM
The Company had net losses of $16.5 million and $50.0 million for the three and nine months ended September 30, 2021, respectively, net losses of $27.6 million and $74.3 million for the three and nine months ended September 30, 2020, respectively, and net cash used in operating activities of $40.0 million and $61.6 million for the nine months ended September 30, 2021 and 2020, respectively. To date, none of the Company’s drug candidates have been approved for sale, and therefore, the Company has not generated any revenue from contracts with customers and does not expect positive cash flows from operations in the foreseeable future.
luck is not going to save it and time draining the cash fast.
LOVE= PEACE= HEALTH= PROSPERITY. NEVER FAILS.....
all my posts are my own opinions only... Do your own DUE DILIGENCE.
Recent UBX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:05:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/11/2023 05:15:29 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/08/2023 09:39:06 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/06/2023 10:25:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 08:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 11:05:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/15/2023 08:08:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/15/2023 08:07:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 08:05:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:07:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/03/2023 08:13:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/03/2023 08:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2023 08:05:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2023 08:04:47 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM